Interações de Flibanserina

WARNING: HYPOTENSION and SYNCOPE IN CERTAIN SETTINGS Interaction with Alcohol The use of ADDYI and alcohol together close in time increases the risk of severe hypotension and syncope [see Warnings and Precautions (5.1) ]. (bula de Flibanserina, Advertência em caixa preta)

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (bula de Alprazolam, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Anfetamina, Advertências e precauções)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (bula de Anfetamina + dextroanfetamina, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (bula de Azelastina + fluticasona, Advertências e precauções)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (bula de Azul de metileno, Interações medicamentosas)

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (bula de Beladona + ópio, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Buprenorfina, Advertência em caixa preta)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Buprenorfina + naloxona, Interações medicamentosas)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (bula de Buspirona, Advertências)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Butalbital + paracetamol + cafeína + codeína, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Butorfanol, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (bula de Carbinoxamina, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (bula de Cetamina, Interações medicamentosas)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (bula de Cetirizina, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (bula de Ciclobenzaprina, Interações medicamentosas)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (bula de Ciprofloxacino, Interações medicamentosas)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Citalopram, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (bula de Clonidina, Advertências e precauções)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Codeína, Advertência em caixa preta)

P-glycoprotein The concomitant use of colchicine capsules and inhibitors of P-glycoprotein (e.g. clarithromycin, ketoconazole, cyclosporine, etc.) should be avoided due to the potential for serious and life-threatening toxicity [see Warnings and Precautions (5.3) and Clinical Pharmacology (12) ] . (bula de Colchicina, Interações medicamentosas)

Avoid use of PRADAXA Capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) [see Drug Interactions (7.1) and Use in Specific Populations (8.6) ] . (bula de Dabigatrana, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Desvenlafaxina, Advertências e precauções)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (bula de Dextroanfetamina, Advertências)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (bula de Difenoxilato + atropina, Contraindicações)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (bula de Duloxetina, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Combinar a erva-de-são-joão (hipérico) com antidepressivos e outros medicamentos serotoninérgicos aumenta o risco de síndrome serotoninérgica. (NCCIH, St. John's Wort)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (bula de Escitalopram, Advertências e precauções)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (bula de Eszopiclona, Advertências e precauções)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (bula de Fenelzina, Contraindicações)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Fentanila, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

If concomitant use of PROZAC with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases ( 5.2 ) (bula de Fluoxetina, Advertências e precauções)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Fluvoxamina, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of granisetron and other serotonergic drugs. (bula de Granisetrona, Advertências e precauções)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Hidrocodona, Advertência em caixa preta)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (bula de Hidrocodona + clorfeniramina, Advertência em caixa preta)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (bula de Hidrocodona + homatropina, Advertência em caixa preta)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (bula de Hidrocodona + ibuprofeno, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Hidrocodona + paracetamol, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (bula de Hidromorfona, Advertência em caixa preta)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (bula de Hidroxizina, Precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (bula de Levocetirizina, Advertências e precauções)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Levomilnaciprana, Advertências e precauções)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Levorfanol, Advertência em caixa preta)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Lisdexanfetamina, Advertências e precauções)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (bula de Lítio, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (bula de Lorazepam, Advertências e precauções)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (bula de Metadona, Advertência em caixa preta)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Metanfetamina, Advertências e precauções)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (bula de Metaxalona, Advertências e precauções)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (bula de Midazolam, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Serotonin Syndrome : Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. (bula de Mirtazapina, Advertências e precauções)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Morfina, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Nalbufina, Advertência em caixa preta)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (bula de Nalmefeno, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

If concomitant use of olanzapine and fluoxetine capsules with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases ( 5.6 ) (bula de Olanzapina + fluoxetina, Advertências e precauções)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Oliceridina, Advertência em caixa preta)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (bula de Olopatadina, Advertências e precauções)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (bula de Olopatadina + mometasona, Advertências e precauções)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. (bula de Oxibato de sódio, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Oxicodona, Advertência em caixa preta)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (bula de Oxicodona + paracetamol, Advertência em caixa preta)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Oximorfona, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (bula de Palonosetrona, Advertências e precauções)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Paracetamol + codeína, Advertência em caixa preta)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Paroxetina, Advertências e precauções)

Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (bula de Pazopanibe, Interações medicamentosas)

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (bula de Pentazocina + naloxona, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Petidina (meperidina), Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (bula de Prometazina + codeína, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Remifentanila, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

• Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. (bula de Rimegepanto, Interações medicamentosas)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Sertralina, Advertências e precauções)

• Avoid concomitant use with strong CYP3A4/P-gp inducers or strong CYP3A4/P-gp inhibitors that decrease or increase sirolimus concentrations ( 7.4 , 12.3 ). (bula de Sirolimo, Interações medicamentosas)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Effect of Other Drugs on TALZENNA Effect of P-gp Inhibitors Breast Cancer Avoid coadministration of TALZENNA with the following P-gp inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil. (bula de Talazoparibe, Interações medicamentosas)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Tapentadol, Advertência em caixa preta)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (bula de Flibanserina, Interações medicamentosas)

Avoid concomitant use HYCAMTIN capsules with P-gp inhibitors or BCRP inhibitors. (bula de Topotecano, Interações medicamentosas)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Tramadol, Advertência em caixa preta)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (bula de Tramadol + paracetamol, Advertência em caixa preta)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with MAOIs when used concomitantly with other serotonergic drugs. (bula de Tranilcipromina, Advertências e precauções)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (bula de Trazodona, Advertências e precauções)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (bula de Triazolam, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Vilazodona, Advertências e precauções)

Therefore, the concomitant use of P-gp inhibitors or inducers should be avoided. (bula de Vincristina, Interações medicamentosas)

Contraindicated with Strong or Moderate CYP3A4 Inhibitors The concomitant use of ADDYI and moderate or strong CYP3A4 inhibitors increases flibanserin concentrations, which can cause severe hypotension and syncope [see Warnings and Precautions (5.2) ] . (bula de Flibanserina, Advertência em caixa preta)

• Serotonin Syndrome : Increased risk when coadministered with other serotonergic agents, but also when taken alone. (bula de Vortioxetina, Advertências e precauções)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (bula de Zaleplona, Advertências)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Ziprasidona, Advertências e precauções)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (bula de Zolpidem, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

P-glycoprotein (P-gp) Inhibitors : Co-administration of P-gp inhibitors can increase afatinib exposure. (bula de Afatinibe, Interações medicamentosas)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (bula de Alopurinol, Advertências e precauções)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (bula de Aminofilina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (bula de Bictegravir + entricitabina + tenofovir alafenamida, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Use with CNS depressants may result in an additive or potentiating effect. (bula de Brimonidina, Interações medicamentosas)

Use with CNS depressants may result in an additive or potentiating effect. (bula de Brimonidina + timolol, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (bula de Bupivacaína, Advertências e precauções)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (bula de Bupivacaína + epinefrina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (bula de Deutetrabenazina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Other CNS Depressants Examples Diphenhydramine, opioids, hypnotics, benzodiazepines Clinical Implications The concomitant use of ADDYI with CNS depressants may increase the risk of CNS depression (e.g., somnolence) compared to the use of ADDYI alone. (bula de Flibanserina, Interações medicamentosas)

Digoxin or Other P-glycoprotein Substrates Examples Digoxin, sirolimus Clinical Implications The concomitant use of ADDYI with digoxin, a drug that is transported by P-glycoprotein (P-gp), increases the digoxin concentration [see Clinical Pharmacology (12.3) ] . (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

…grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport,… (bula de Dofetilida, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

P-gp Inhibitors Treatment of NVAF Based on clinical experience from the ENGAGE AF-TIMI 48 study, dose reduction in patients concomitantly receiving P-gp inhibitors resulted in edoxaban blood levels that were lower than in patients who were given the full dose. (bula de Edoxabana, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Coadministration of DESCOVY with other drugs that inhibit P-gp and BCRP may increase the absorption and plasma concentration of TAF. (bula de Entricitabina + tenofovir, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) via P-gp inhibition; however, concomitant P-gp inhibitor use had no attributable effect on safety or treatment outcome of fidaxomicin-treated adult patients in controlled clinical trials. (bula de Fidaxomicina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Multiple Concomitant Weak CYP3A4 Inhibitors Concomitant use of multiple weak CYP3A4 inhibitors that may include herbal supplements (e.g., ginkgo, resveratrol) or non-prescription drugs (e.g., cimetidine) could also lead to clinically relevant increases in flibanserin concentrations that may increase the risk of hypotension and syncope [see Drug Interactions (7)… (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (bula de Lidocaína + epinefrina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Drug Interactions Effects of Other Drugs on Loperamide Concomitant use of loperamide hydrochloride capsules with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide. (bula de Loperamida, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (bula de Metirosina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (bula de Naldemedina, Interações medicamentosas)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (bula de Naloxona, Advertências e precauções)

…malformation, central nervous system tumor or infection, or metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia) excessive use of alcohol or sedatives, addiction to cocaine or stimulants, or withdrawal from sedatives patients with diabetes treated with insulin and/or oral diabetic medications (sulfonylureas and meglitinides)… (bula de Naltrexona + bupropiona, Advertências e precauções)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Strong CYP2C19 Inhibitors Examples Proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, antifungals Clinical Implications The concomitant use of ADDYI with strong CYP2C19 inhibitors may increase flibanserin exposure which may increase the risk of hypotension, syncope, and CNS depression. (bula de Flibanserina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Weak CYP3A4 Inhibitors Examples Oral contraceptives, cimetidine, fluoxetine, ginkgo, ranitidine Clinical Implications The concomitant use of ADDYI with multiple weak CYP3A4 inhibitors may increase the risk of adverse reactions. (bula de Flibanserina, Interações medicamentosas)

• Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (bula de Rifaximina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (bula de Teofilina, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

…telaprevir, telithromycin and conivaptan Examples of moderate CYP3A4 inhibitors Amprenavir, atazanavir, ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil, and grapefruit juice Clinical Implications The concomitant use of ADDYI with moderate or strong CYP3A4 inhibitors increases flibanserin exposure compared to the use of ADDYI alone. (bula de Flibanserina, Interações medicamentosas)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (bula de Triexifenidil, Interações medicamentosas)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (bula de Trimetobenzamida, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (bula de Flibanserina, Advertências e precauções)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (bula de Alfaepoetina, Advertências e precauções)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (bula de Bupropiona, Advertências e precauções)

Dapagliflozin or dapagliflozin 3-O-glucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. (bula de Dapagliflozina, Interações medicamentosas)

Digoxin Quinidine is an inhibitor of P-glycoprotein. (bula de Dextrometorfano + quinidina, Interações medicamentosas)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (bula de Doxapram, Advertências)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (bula de Eribulina, Interações medicamentosas)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (bula de Fentermina, Advertências e precauções)

P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (bula de Lomitapida, Interações medicamentosas)

Substrates and Inhibitors of P-glycoprotein It has been shown in vitro that mefloquine is a substrate and an inhibitor of P-glycoprotein. (bula de Mefloquina, Interações medicamentosas)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (bula de Prazosina, Interações medicamentosas)

Quinine inhibits P-gp and has the potential to affect the transport of drugs that are P-gp substrates. (bula de Quinina, Interações medicamentosas)

Strong P-glycoprotein (P-gp) Inhibitors In vitro studies indicated that silodosin is a P‑gp substrate. (bula de Silodosina, Interações medicamentosas)

Mechanism and Clinical Effect(s) Vepdegestrant is a P-gp inhibitor. (bula de Vepdegestranto, Interações medicamentosas)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (bula de Montelucaste, Interações medicamentosas)